AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab
- 25 July 2013
- journal article
- case report
- Published by Taylor & Francis Ltd in Amyloid
- Vol. 20 (4), 275-276
- https://doi.org/10.3109/13506129.2013.838947
Abstract
Amyloid A (AA) (secondary) amyloidosis represents a severe complication of chronic inflammatory diseases. Since pathogenic mechanisms point to the central role of interleukin 6 (IL-6) in the process of amyloid AA generation, IL-6 blockade seems an attractive therapeutic option. We report a case of a patient with polyarteritis nodosa complicated by AA amyloidosis treated with tocilizumab.Keywords
This publication has 8 references indexed in Scilit:
- Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritisAmyloid, 2012
- Clinical Immunology Review Series: An approach to the patient with a periodic fever syndromeClinical and Experimental Immunology, 2011
- Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritisClinical Rheumatology, 2010
- Amyloidosis in Ankylosing SpondylitisJCR: Journal of Clinical Rheumatology, 2009
- Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritisClinical Rheumatology, 2009
- Natural History and Outcome in Systemic AA AmyloidosisThe New England Journal of Medicine, 2007
- Essential role of STAT3 in cytokine‐driven NF‐κB‐mediated serum amyloid A gene expressionGenes to Cells, 2005
- Classic Polyarteritis Nodosa Associated with Renal AmyloidosisNephron, 1999